Meeting
2022 ASCO Annual Meeting
Development and validation of Duoseq as a novel diagnostic and companion assay for lymphoma and other cancers.
Authors
Chrissie Rozzi
Data Driven Bioscience, Durham, NC
Chrissie Rozzi , Stacey O'Neill , Eric D. Hsi , Magdalena Czader , Lin Wang , Elizabeth Thacker , Lanie Happ , Clay Parker , Sandeep Dave
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3074)
DOI
10.1200/JCO.2022.40.16_suppl.3074
Abstract #
3074
Poster Bd #
66
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial.
First Author: Franck Morschhauser
Poster
2019 ASCO Annual Meeting
Molecular profiling of primary central nervous system lymphoma as compared to activated B-cell subtype of diffuse large B-cell lymphoma.
First Author: Mohamad Barakat
Poster
2019 ASCO Annual Meeting
Outcomes of lenalidomide in diffuse large B-cell (DLBCL) and high-grade NHL (HGBCL): A single-center retrospective analysis.
First Author: Thomas David Rodgers
Poster
2017 ASCO Annual Meeting
Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
First Author: Georg Lenz